Could a weight loss drug ease long COVID's debilitating fatigue?
NCT ID NCT07128082
Summary
This study is testing whether the medication tirzepatide (brand name Zepbound) can reduce symptoms of Long COVID, especially severe fatigue. It involves 1,000 adults in the U.S. with Long COVID who will be randomly assigned to take either the real medication or a placebo pill for 12 months. The entire study is conducted remotely from participants' homes to see if the drug improves their energy levels and overall health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Scripps Research
La Jolla, California, 92037, United States
Conditions
Explore the condition pages connected to this study.